公开(公告)号：US12234272B2

公开(公告)日：2025-02-25

申请号：US17709296

申请日：2022-03-30

Applicant: Ferring B.V.

Inventor： Ian Cottingham ,  Daniel Plaksin ,  Richard White

IPC: C07K14/575 ,  A61K38/16 ,  C07K14/59 ,  C12P21/00

Abstract: Described are pharmaceutical compositions comprising recombinant human chorionic gonadotropin (hCG) and optionally follicle stimulating hormone (FSH), wherein the recombinant hCG in the composition comprises α2,3- and α2,6-sialylation and comprises mono-(1S), di-(2S), tri-(3S) and tetra-(4S) sialylated glycan structures. The recombinant hCG may be obtained by expression in a human cell line, such as the PER.C6 cell line, optionally wherein the cell line is modified using α2,3-sialyltransferase.

公开(公告)号：US20250034206A1

公开(公告)日：2025-01-30

申请号：US18717177

申请日：2022-12-07

Applicant: FERRING B.V.

Inventor： Eyal KAMHI ,  Michelle MINTZ ,  Jenny AHARONOV ,  Elinor EREZ

IPC: C07K1/22

Abstract: The present invention provides methods for use in protein purification. The disclosed methods help avoid precipitation events and can be used to improve the performance and/or efficiency of protein purification protocols. The methods may be used to improve or prepare solutions for use in protein purification and/or protein extraction processes. One particular application of the disclosed method is in affinity chromatography where it may be applied to the preparation of load solutions.

公开(公告)号：US20240398704A1

公开(公告)日：2024-12-05

申请号：US18697370

申请日：2022-09-30

Applicant: FERRING B.V.

Inventor： BijayKumar PADHI ,  Shailesh Vishwanath BIRADAR ,  Ambedkar Sunil SONGA

IPC: A61K9/00 ,  A61K9/107 ,  A61K31/4166 ,  A61K47/10 ,  A61K47/14 ,  A61K47/44

Abstract: Described herein are oral liquid pharmaceutical compositions comprising enzalutamide and therapeutic methods for using them.

公开(公告)号：US20240342230A1

公开(公告)日：2024-10-17

申请号：US18427221

申请日：2024-01-30

Applicant: FERRING B.V. ,  INSTITUT PASTEUR

Inventor： Pascal Danglas ,  Laurent Debarbieux

IPC: A61K35/76 ,  A61K9/00 ,  C12N7/00

CPC classification number: A61K35/76 ,  A61K9/0053 ,  C12N7/00 ,  C12N2795/10021 ,  C12N2795/10132 ,  C12N2795/10171 ,  Y02A50/30

Abstract: The subject invention provides a pharmaceutical composition comprising: (i) at least one bacteriophage strain(s) capable of producing a lytic infection in an adherent-invasive Escherichia coli strain; and (ii) a pharmaceutically acceptable carrier; for the treatment of inflammatory bowel disease.
The subject invention further provides a method of treating inflammatory bowel disease comprising administering to a subject in need thereof at least one bacteriophage strain capable of producing a lytic infection in an adherent-invasive Escherichia coli strain thereby treating the subject.
The subject invention also provides new bacteriophage strains.

公开(公告)号：US20240287468A1

公开(公告)日：2024-08-29

申请号：US18570436

申请日：2022-06-14

Applicant: Ferring B.V.

Inventor： Kristin WANNERBERGER ,  Alexander SULAKVELIDZE

IPC: C12N7/00 ,  A61K35/741 ,  A61K35/76 ,  A61K36/064 ,  A61K39/00 ,  A61K39/09 ,  A61P31/04

CPC classification number: C12N7/00 ,  A61K35/741 ,  A61K35/76 ,  A61K36/064 ,  A61K39/09 ,  A61P31/04 ,  A61K2039/521 ,  C12N2795/00021 ,  C12N2795/00032

Abstract: Described herein are bacteriophages that infect and lyse Vancomycin-Resistant Enterococci (VRE). The bacteriophages are useful, for example, for the prophylactic or therapeutic treatment of subjects infected with Enterococci, including VRE, or who are at risk of infection by Enterococci, including VRE, and for other uses described herein.

公开(公告)号：US20230372447A1

公开(公告)日：2023-11-23

申请号：US18138000

申请日：2023-04-21

Applicant: Ferring B.V.

Inventor： Helen Ulrika Sjögren ,  Charlott Hojer-Pedersen

IPC: A61K38/24 ,  A61K9/00 ,  A61K47/18 ,  A61K9/08 ,  A61P15/08 ,  A61K47/26 ,  A61K47/10

CPC classification number: A61K38/24 ,  A61K9/0019 ,  A61K47/183 ,  A61K9/08 ,  A61P15/08 ,  A61K47/26 ,  A61K47/10

Abstract: The present invention pertains in general to the field of the stabilization of gonadotropin formulations, in particular liquid formulations of gonadotropins. The stabilization is achieved by a particular combination of excipients, preferably arginine and methionine. In a preferred embodiment, the formulation does not comprise a buffer.

公开(公告)号：US20230357322A1

公开(公告)日：2023-11-09

申请号：US18142470

申请日：2023-05-02

Applicant: Ferring B.V.

Inventor： Elizabeth Serrano CHAVEZ ,  Helen SJOEGREN ,  Jette BOLL ,  Hayley REECE ,  Jonathan James LOUGHREY

IPC: C07K7/16

CPC classification number: C07K7/16 ,  C07B2200/13

Abstract: The present invention relates to crystalline forms of carbetocin, a method of their manufacture, and pharmaceutical compositions thereof.

公开(公告)号：US20230346704A1

公开(公告)日：2023-11-02

申请号：US18128922

申请日：2023-03-30

Applicant: Ferring B.V.

Inventor： Ganeshchandra SONAVANE ,  Parag LOKHANDE ,  Pradeep SETHI ,  Tushar WAGH

IPC: A61K9/16 ,  A61K31/4545 ,  A61K31/519 ,  A61K9/19 ,  A61K31/4725

CPC classification number: A61K9/1623 ,  A61K9/1664 ,  A61K9/1682 ,  A61K9/19 ,  A61K31/4545 ,  A61K31/4725 ,  A61K31/519

Abstract: A free-flowing solid pharmaceutical formulation comprising one or more active ingredients and a blend comprising sorbitol and liquid paraffin, a package containing the formulation, a process for the manufacture of the formulation and the use of the blend in the formulation.

公开(公告)号：US11752157B2

公开(公告)日：2023-09-12

申请号：US16877186

申请日：2020-05-18

Applicant: Ferring B.V.

Inventor： Joan-Carles Arce

IPC: A61K31/404 ,  A61B17/435 ,  A61K31/57 ,  A61K38/095 ,  A61K38/12 ,  A61K45/06 ,  A61K31/4045 ,  A61K31/565 ,  A61K9/00

CPC classification number: A61K31/57 ,  A61B17/435 ,  A61K9/0019 ,  A61K9/0034 ,  A61K31/404 ,  A61K31/4045 ,  A61K31/565 ,  A61K38/095 ,  A61K38/12 ,  A61K45/06 ,  A61K31/4045 ,  A61K2300/00 ,  A61K31/57 ,  A61K2300/00 ,  A61K31/565 ,  A61K2300/00

Abstract: The present invention relates to the use of an oxytocin receptor antagonist in females undergoing embryo transfer as part of an assisted reproductive technology. In particular, methods are provided for increasing ongoing implantation rate, increasing ongoing pregnancy rate, increasing clinical pregnancy rate, and/or increasing live birth rate in a female subject undergoing embryo transfer. Specifically, the antagonists are released in the luteal phase when the endometrium is receptive for embryo implantation and/or when the embryo has reached the blastocyst-stage.

公开(公告)号：US11712422B2

公开(公告)日：2023-08-01

申请号：US17117599

申请日：2020-12-10

Applicant: FERRING B.V.

Inventor： Soren Halskov

IPC: A61K9/50 ,  A61K9/00 ,  A61K33/44 ,  A61K9/20 ,  A61P1/00

CPC classification number: A61K9/5073 ,  A61K9/0095 ,  A61K9/5026 ,  A61K9/5042 ,  A61K9/5047 ,  A61K33/44 ,  A61K9/2081

Abstract: The invention provides a pharmaceutical composition comprising activated carbon particles, for oral administration. The pharmaceutical composition may be for (use in) the treatment of gastrointestinal fistula.